DK3094322T3 - Administration af tasimelteon i fastende tilstand - Google Patents

Administration af tasimelteon i fastende tilstand Download PDF

Info

Publication number
DK3094322T3
DK3094322T3 DK15701861.5T DK15701861T DK3094322T3 DK 3094322 T3 DK3094322 T3 DK 3094322T3 DK 15701861 T DK15701861 T DK 15701861T DK 3094322 T3 DK3094322 T3 DK 3094322T3
Authority
DK
Denmark
Prior art keywords
tasimelteon
administration
fixed mode
mode
fixed
Prior art date
Application number
DK15701861.5T
Other languages
English (en)
Inventor
Marlene Michelle Dressman
Mihael H Polymeropoulos
Paolo Baroldi
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53520399&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3094322(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3094322T3 publication Critical patent/DK3094322T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
DK15701861.5T 2014-01-14 2015-01-07 Administration af tasimelteon i fastende tilstand DK3094322T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461927465P 2014-01-14 2014-01-14
US14/511,669 US10376487B2 (en) 2013-11-12 2014-10-10 Method of treatment
PCT/US2015/010410 WO2015108728A1 (en) 2014-01-14 2015-01-07 Administration of tasimelteon under fasted conditions

Publications (1)

Publication Number Publication Date
DK3094322T3 true DK3094322T3 (da) 2020-07-20

Family

ID=53520399

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15701861.5T DK3094322T3 (da) 2014-01-14 2015-01-07 Administration af tasimelteon i fastende tilstand

Country Status (20)

Country Link
US (4) US10376487B2 (da)
EP (1) EP3094322B1 (da)
JP (3) JP2017502996A (da)
KR (3) KR102276569B1 (da)
CN (2) CN107072978A (da)
AU (3) AU2015206797A1 (da)
CA (2) CA2936504C (da)
CL (1) CL2016001794A1 (da)
DK (1) DK3094322T3 (da)
ES (1) ES2805451T3 (da)
HK (1) HK1231404A1 (da)
HR (1) HRP20201069T1 (da)
HU (1) HUE051244T2 (da)
IL (1) IL246676B (da)
MX (1) MX2016009231A (da)
NZ (1) NZ722254A (da)
PT (1) PT3094322T (da)
SI (1) SI3094322T1 (da)
WO (1) WO2015108728A1 (da)
ZA (1) ZA201605103B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090105333A1 (en) * 2006-05-22 2009-04-23 Gunther Birznieks Melatonin agonist treatment
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR20180100450A (ko) 2012-01-26 2018-09-10 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
DK3188727T3 (da) 2014-09-02 2023-02-06 Vanda Pharmaceuticals Inc Tasimelteon til behandling af smith-magenis¿ syndrom
ES2965488T3 (es) 2017-08-02 2024-04-15 Vanda Pharmaceuticals Inc Uso de tasimelteón para el tratamiento de trastornos afectivos en pacientes mayoritariamente negroafricanos
JP2022500420A (ja) * 2018-09-12 2022-01-04 バンダ・ファーマシューティカルズ・インコーポレイテッドVanda Pharmaceuticals Inc. 睡眠又は睡眠後パフォーマンスの改善
MX2022006577A (es) 2019-12-13 2022-07-04 Vanda Pharmaceuticals Inc Formulaciones liquidas de tasimelteon y metodos para su uso.
CA3229930A1 (en) 2021-09-14 2023-03-23 Mihael Polymeropoulos Treatment of sleep disturbances in autism spectrum disorder patients

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL50699A0 (en) 1975-10-28 1976-12-31 Ici America Inc Triazole derivatives
EP0126630B1 (en) 1983-05-18 1987-09-16 Monash University The use of melatonin for the manufacture of a medicament
IL79264A0 (en) 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
US4997845A (en) 1987-02-02 1991-03-05 Eli Lilly And Company β-alkylmelatonins as ovulation inhibitors
US5093352A (en) 1988-11-14 1992-03-03 Whitby Research, Inc. Antidepressant agents
US5151446A (en) 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US6638963B1 (en) 1990-12-04 2003-10-28 Oregon Health And Science University Methods for treating circadian rhythm disorders
US5242941A (en) 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
IT1251544B (it) 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
US6180657B1 (en) 1993-11-18 2001-01-30 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
GB9416884D0 (en) 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
MD1716C2 (ro) 1995-02-01 2002-02-28 Neurim Pharmaceuticals (1991) Ltd. Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine
AU713030B2 (en) 1995-10-24 1999-11-18 Gruenenthal Gmbh Method of adjusting the circadian rhythm of a mammal
ZA9711051B (en) 1996-12-10 1999-06-09 Bristol Myers Squibb Co Benzodioxole benzofuran dihydrobenzofuran and benzodioxane melatonergic agents
US5776969A (en) 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
AUPO588297A0 (en) 1997-03-26 1997-04-24 Luminis Pty Limited Mediation in melatonin production
CN1206996C (zh) 1998-06-09 2005-06-22 武田药品工业株式会社 用于治疗或预防睡眠障碍的药物组合物
US6562858B2 (en) 1999-05-17 2003-05-13 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating depression
AU763963B2 (en) 1999-06-30 2003-08-07 Bristol-Myers Squibb Company Heterocyclic aminopyrrolidine derivatives as melatonergic agents
CN101912367A (zh) 2001-10-30 2010-12-15 诺瓦提斯公司 伊潘立酮和星状聚合物的贮库制剂
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
JP2005080603A (ja) 2003-09-10 2005-03-31 Kumamoto Technology & Industry Foundation 生体リズム障害の度合の判断方法
WO2005063240A1 (en) 2003-12-22 2005-07-14 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
EP1696959A2 (en) 2003-12-24 2006-09-06 Sepracor, Inc. Melatonin combination therapy for improving sleep quality
JP5017268B2 (ja) 2005-07-29 2012-09-05 ヴァンダ ファーマシューティカルズ インコーポレイテッド 覚醒を改善する方法
US7754902B2 (en) 2006-05-18 2010-07-13 Vanda Pharmaceuticals, Inc. Ruthenium(II) catalysts for use in stereoselective cyclopropanations
WO2007137247A2 (en) 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Treatment for depressive disorders
US20090105333A1 (en) 2006-05-22 2009-04-23 Gunther Birznieks Melatonin agonist treatment
WO2008011150A1 (en) 2006-07-20 2008-01-24 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
WO2008011120A2 (en) 2006-07-21 2008-01-24 The Regents Of The University Of California Human endogenous retrovirus polypeptide compositions and methods of use thereof
US20110077200A1 (en) 2006-12-06 2011-03-31 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
KR20100016445A (ko) 2007-04-11 2010-02-12 바이오마린 파머수티컬 인크. 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
JP5590676B2 (ja) 2007-09-13 2014-09-17 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｐｅｒ３ｖｎｔｒ遺伝子型に基づく睡眠パラメータ及び睡眠誘導化合物に対する応答の予測
WO2009084023A2 (en) 2007-10-19 2009-07-09 Glenmark Generics Limited Amorphous ramelteon and process for the preparation thereof
EP2215073A4 (en) 2007-10-31 2011-04-06 Merck Sharp & Dohme SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS
JP5558016B2 (ja) 2009-03-17 2014-07-23 株式会社 資生堂 概日リズム調整剤
MX2011010525A (es) 2009-04-07 2012-04-02 Duocort Pharma Ab Terapia mejorada con glucocorticoides.
EP2453891A1 (en) 2009-07-16 2012-05-23 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
KR20180100450A (ko) 2012-01-26 2018-09-10 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
EP3470405A1 (en) 2014-02-12 2019-04-17 Vanda Pharmaceuticals Inc. Highly purified pharmaceutical grade tasimelteon

Also Published As

Publication number Publication date
KR102276569B1 (ko) 2021-07-12
CA3091827A1 (en) 2015-07-23
CA2936504C (en) 2020-10-13
US11786502B2 (en) 2023-10-17
JP2021102634A (ja) 2021-07-15
KR20200106094A (ko) 2020-09-10
HK1231404A1 (zh) 2017-12-22
KR101970050B1 (ko) 2019-04-17
US11141400B2 (en) 2021-10-12
CN116115551A (zh) 2023-05-16
EP3094322B1 (en) 2020-04-08
US20210379008A1 (en) 2021-12-09
US20200188346A1 (en) 2020-06-18
NZ722254A (en) 2022-07-01
AU2020202719A1 (en) 2020-05-14
EP3094322A1 (en) 2016-11-23
JP2017502996A (ja) 2017-01-26
HRP20201069T1 (hr) 2020-10-30
MX2016009231A (es) 2016-10-05
CN107072978A (zh) 2017-08-18
US10610511B2 (en) 2020-04-07
WO2015108728A1 (en) 2015-07-23
IL246676A0 (en) 2016-08-31
US20190336470A1 (en) 2019-11-07
JP2023024704A (ja) 2023-02-16
AU2020202719B2 (en) 2022-03-10
CL2016001794A1 (es) 2017-04-28
ES2805451T3 (es) 2021-02-12
US20170087122A9 (en) 2017-03-30
KR20160106735A (ko) 2016-09-12
AU2015206797A1 (en) 2016-08-04
US20150196527A1 (en) 2015-07-16
ZA201605103B (en) 2023-07-26
SI3094322T1 (sl) 2020-08-31
RU2016133348A (ru) 2018-02-20
HUE051244T2 (hu) 2021-03-01
PT3094322T (pt) 2020-07-14
KR102154458B1 (ko) 2020-09-09
KR20190040102A (ko) 2019-04-16
CA2936504A1 (en) 2015-07-23
IL246676B (en) 2020-10-29
AU2022201953A1 (en) 2022-04-14
US10376487B2 (en) 2019-08-13
RU2016133348A3 (da) 2018-09-26

Similar Documents

Publication Publication Date Title
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3132034T3 (da) Terapeutikum
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3220988T3 (da) Intranasal administration
DK3148625T3 (da) Opklappelig kateterpakning
DK3094322T3 (da) Administration af tasimelteon i fastende tilstand
DK3174483T3 (da) Hyporørkonstruktion
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
FI20145185A (fi) Liikkeenrajoitinrakenne
MA41266A (fr) Cataplasme
DK3418273T3 (da) Derivater af flavagliner
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3018383T3 (da) Afslutning af styrkeelementer i dybhavskabler
DK3173071T3 (da) Formularing af maropitant
DK3155422T3 (da) Demaskering af endotoxiner i opløsning
DK3200783T3 (da) Behandling af erytromelalgi
DK2944309T3 (da) Anvendelse af palmitoylethanolamid i kombination med opioider
DK3148513T3 (da) Ceritinib-formulering
DK3129427T3 (da) Drastisk reduktion af viskositet i biomasse
DK3154942T3 (da) Fremstilling af piperidin-4-carbothioamid
DK3104839T3 (da) Topiske formuleringer af heparin
DK3193856T3 (da) Formulering
DK3417873T3 (da) Ultrarene hypoallergene opløsninger af sacrosidase
ITBG20150006U1 (it) Easy braces
CU20140011S4 (es) Juego de sillas combinadas